Wouter J. Plattel - Concepedia

Author

Wouter J. Plattel

University Medical Center Groningen ORCID

Also Known As

W J Plattel, W Plattel, W. J. Plattel, W. Plattel, W.J. Plattel, Wouter J. Plattel, Wouter J Plattel, Wouter J. Plattel, Wouter Johannes Plattel, Wouter Plattel

Publications

876

Citations

H-Index

Concepts

All Affiliations

University Medical Center Groningen Amsterdam University Medical Centers University of Groningen Erasmus MC Cancer Institute Radboud University Medical Center

About

Wouter J. Plattel is an author at University Medical Center Groningen specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	287
2	Pathology	7	7	287
3	Immunology	4	4	231
4	Health Sciences	2	2	84
5	Cell Biology	1	1	26

Wouter J. Plattel

Publications

704

Citations

H-Index

Page 1

	Year	Citations
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study Marie José Kersten, Julia Driessen, Josée M. Zijlstra, Haematologica ImmunologyPathologyPrimary RefractoryImmunotherapyHematological Malignancy	2020	92
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients Simone de Vries, Michael Schaapveld, Cécile P.M. Janus, JNCI Journal of the National Cancer Institute	2020	90
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma Wouter J. Plattel, Anke van den Berg, Leo H. Visser, Haematologica	2011	68
Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study Mirian Brink, Frederik O. Meeuwes, Marjolein van der Poel, Blood Asct ConsolidationAgingDisease ProgressionImmunodeficienciesImmunology	2022	66
Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of <scp>sG</scp>alectin‐1, <scp>sCD</scp>163 and <scp>sCD</scp>30 with TARC Wouter J. Plattel, Zainab N. D. Alsada, Gustaaf W. van Imhoff, British Journal of Haematology ImmunodeficienciesImmunologyPathologyClassical Hodgkin LymphomaImmunotherapy	2016	47
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma Massimo Federico, Catherine Fortpied, Yana Stepanishyna, Journal of Clinical Oncology	2023	42
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma Chuanhui Xu, Wouter J. Plattel, Anke van den Berg, Haematologica	2011	30
Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study Anton Hagenbeek, Josée M. Zijlstra, Wouter J. Plattel, Blood	2018	28
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma Suzanne I.M. Neppelenbroek, Y.M. Geurts, Berthe M.P. Aleman, Journal of Clinical Oncology	2024	27
Insulin-Like Growth Factor 1 Receptor Is a Prognostic Factor in Classical Hodgkin Lymphoma Zheng Liang, Arjan Diepstra, Chuanhui Xu, PLoS ONE Lymphoid NeoplasiaGrowth HormonePrognostic FactorMedicineReceptor Tyrosine Kinase	2014	26

Page 1